Background: B cells are potential sites for latency and reactivation of the human neurotropic JC polyomavirus (JCV).
introduction
Hodgkin's lymphoma (HL) is a malignancy of the immune system where the scarce recognized tumoral Hodgkin and Reed-Sternberg (HRS) cells are, in most cases, derived from germinal center B cells [1] .
Epidemiological, molecular and immunological features of HL indicate that virus could play a role in its etiology. EpsteinBarr virus (EBV), an ubiquitous human DNA herpesvirus, is associated with one-fifth to one-third of classical HL cases and with a poor prognosis [2] .
As EBV, human DNA polyomavirus JC (JCV), a B-lymphotropic, infects a significant proportion of the population [3] . It is a highly preserved virus, with unique family transmission characteristics [4] , detected in B lymphocytes and mononuclear cells in brain perivascular spaces of patients with progressive multifocal leukoencephalopathy. JCV transforms cells, including human B-cell lines, both in vivo and in vitro by interacting with the p53 protein, Rb family proteins and cell cycle regulators that are responsible for chromosomal instability, including aneuploidy mitosis [5] . Those transformed cells, that exhibit multiple and complex chromosomal aberrations when cultured (e.g. di-and tricentrics, translocations, insertions, deletions, acentric fragments), have been called 'rogue' cells [6] . Our previous studies investigated DNA repair and telomere dysfunction in peripheral blood lymphocytes (PBL) of a prospective series of HL patients, in relation to radiation sensitivity, risk of late complications, particularly second cancers [7, 8] . Patients exhibited a wide range of telomere length and chromosomal aberrations, some of them with very short telomeres and increased radiation sensitivity. Both features were also found in patients who presented later with a second cancer. The presence of rogue cells in the PBL of HL patients under treatment, and sometimes before treatment, prompted us to investigate JCV in lymphomas [9, 10] .
We speculated that the activation of JCV with EBV could account for increased chromosome aberrations and appearance of rogue cells and could influence adversely the course of disease.
patients and methods
patients Two cohorts were studied: 74 HL patients followed up at the Institut Gustave Roussy from 1997 to 2005 (Table 1) and 91 B-cell non-Hodgkin's lymphoma (B-NHL) patients (excluding Burkitt's lymphoma with 58 males/33 females, mean age 55.7 years (17-75), Ann Arbor stage I 24, II 36, III 17, IV 14) . The tumors were reviewed (JB) [11] . Treatment was standard: all patients underwent initial chemotherapy (CT), and radiation therapy (RT) was given in 55 of 74 HL patients and 54 of 91 B-NHL patients and rituximab in 5 of 91 NHL patients. Response criteria were standard. The median follow-up for blood sampling and survival was 75 months . The control populations consisted of 30 healthy donors (mean age 40 years; range 19-66; males 12, females 18) and 70 patients with newly diagnosed untreated solid tumors [mean age 41 years; range 18-69; males 25, females 45; thyroid (n = 35), urinary tract (n = 15), head and neck (n = 20)]. Blood was sampled before treatment, after CT, after RT and, when feasible, at intervals from initial treatment.
The study was approved by the ethics committee (approval no. 97-56.). All subjects signed an informed consent form. methods PCR procedure and sequencing. A nested PCR, which amplifies a part of the region encoding for the large T antigen [12] , was carried out to detect JCV DNA.
The PCR products from the second amplification were sequenced with the Big Dye terminator cycle Sequencing Kit (Applied Biosystems, Marne la Vallée, France) on an ABI 3100 Automated Sequencer. Sequences were analyzed with Sequence Navigator software (http://www.infobiogen.fr/ services/analyseq/cgi-bin/clustalw_in.pl). The JCV T-antigen DNA sequences corresponding to 11 positive HL specimens were entered in the EMBL database under the following accession numbers (AM712480-AM712490).
PBL culture. Blood was cultured in a medium with phytohemagglutinin M for 48 h, incubated at 37°C for 2 h with colcemid before harvesting. Slides were prepared after standard methanol/acetic (3/1, by vol) fixation and stored at 220°C until use [7] .
DNA probes and FISH. FISH detection of JCV DNA was on the basis of three different probes, thus reducing the likelihood of very low level nonspecific staining.
JCV Probe 1: Biotin-labeled JC virus Probe (Enzo Diagnosis, Farmingdale, NY). Probe 2: 5# bCTT TTT AGG TGG GGT AGA GTG TTG GGA GGA TCC TGTT GTT TTC A 3# (T-antigen, nucleotide position 4283-4320, MAD-1 strain) [13] . Probe 3: 5# bGAT GAA TGT GCA CTC TAA TGG GCA AGC 3# (T-antigen, nucleotide position 4253-4260, MAD-1 strain) [14] .
EBV Probe: 5# GGG GCA AAA TAC TGT GTT AG 3# [thymidine kinase 'BXLF1'gene, nucleotide position 131122-131136, human herpesvirus 4 strain (AJ507799)] [15] .
FISH was done as previously described [16] . Each hybridization was repeated three times and the same result was obtained. On the basis of these findings, the sensitivity and specificity were considered as adequate.
statistical analysis
Proportions were compared with Fisher's exact tests. Freedom from progression (FFP) was estimated as the interval between the start of treatment and the date of relapse or progression. FFP curves were estimated with the Kaplan-Meier method and compared using log-rank tests.
results prevalence of JCV and EBV in PBL of HL patients PCR product sequencing of PBL confirmed the identity of JCV in 42 (57%) HL patients during treatment ( Figure 1A and B). 
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In this study, we introduced FISH technique as a new approach to detect and localize viral infection. The specificity and the sensitivity of FISH technique were assessed with PBL from JCV positive-progressive multifocal leukoencephalopathy (PML) patients after controlling for the positivity by PCR. FISH with the JCV DNA probe produced multiple spots in the nucleus and cytoplasm in PBL from PML patients, indicative of JCV activation (Figure 2A) . Similarly, the EBV cell line exhibited many spots per nucleus. The number of spots per nucleus was stratified for both EBV and JCV as in previous EBV studies [17] . No heterogeneity was found between replicate experiments. On the basis of these findings, the sensitivity and specificity were considered as adequate. Table 2 shows the distribution of the types of viral infection in lymphoma patients and controls. Ninety-three percent of the controls exhibited one or two JCV spots in 1% of cells. Before treatment, all blood samples from lymphoma patients exhibited JCV spots (one or two copy numbers) ( Figure 2B ) and a high number (more than two) of spots were observed in a few cells, mostly in HL patients (15%) (Figure 2C and D; P < 10 23 ). original article
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The number of JCV spots in lymphocytes was not related to sex, age, histology or stage. All subjects including healthy donors showed positivity for EBV DNA. A high number of EBV spots were observed in 31% of HL patients ( Figure 2E ) versus 7% in B-NHL (P < 10 24 ) and 13% in controls (P < 10 25 ). After treatment, a high number of JCV spots were significantly increased in HL patients (+40%, P < 10 25 ). In contrast, this increase was significant neither in patients with solid tumors (+4%; P = 0.12) nor in B-NHL patients (+5%; P = 0.44). Oligopeptide probes detected JCV T-antigen RNA in some HL lymphocytes, as multiple cytoplasmic spots ( Figure 2F ), that were reduced after RNase treatment ( Figure 2G) .
The follow-up of patients shows that JCV DNA sequences were not detectable by PCR, and JCV DNA spots in PBL of HL patients were comparable to that observed before treatment (relapsing patients were excluded), indicating a loss of viral DNA.
induction of rogue cells
During the treatment, 40 patients from the HL cohort (55%) exhibited a high number of rogue lymphocytes (P < 10 26 ) ( Figure 3B and C, Table 2 ), while rogue lymphocyte was observed in one patient from the control cohort (1%) treated for a solid tumor (thyroid cancer patient) and in two B-NHL patients (3%).
Multiple steps were identified in the induction of rogue cell in HL patients; first a higher frequency of unstable chromosomal abnormalities in diploid cell which also exhibited a higher number of JCV spots ( Figure 3D) ; second the formation of multiple chromosomal abnormalities in diploid cells exhibiting JCV spots ( Figure 3E) ; finally, polyploid rogue cell bereft of JCV spots were observed ( Figure 3F ).
The activation of both JCV and EBV was observed in 32% of HL patients ( Figure 2H ). These patients exhibited a higher frequency of rogue cells as well as the presence of aneuploid rogue cells compared with patients with only JCV activation (P < 10 25 ). No significant correlation was observed between the type of CT regimens and the size of irradiation field and the frequency of rogue cells.
The proportion of chromosomal aberrations and complex chromosomal rearrangements (CCR) was larger in patients with activated JCV or EBV, especially in patients with co-activation of EBV and JCV, and in the presence of rogue cells (Figure 4 ).
clinical outcome of HL patients
The analysis of prognostic factors concerned only HL patients. The median follow-up was 75 months (3-110). Progression or relapse occurred in 15 patients (20%). None of the patient characteristics listed in Table 1 , nor the European Organization for Research and Treatment of Cancer prognostic scores for stages I-II disease [18] , nor the International Prognostic Score for stages III-IV disease [19] , was significantly related to FFP.
In PBL from HL patients, a co-activation of EBV and JCV virus detected before treatment was associated with shorter FFP (P = 0.08 before treatment and P = 0.001 after) ( Figure 5A and B). The presence of rogue lymphocytes after treatment was a strong predictor of shorter FFP (P = 0.002) ( Figure 5C ).
discussion
A high prevalence of JCV DNA sequences in PBL of HL patients during the course of treatment is reported for the first time; a link between viral activation and chromosomal instability is established and is associated with a shorter FFP.
We demonstrate that JCV sequences are present in circulating lymphocytes and induce in vivo the appearance of rogue lymphocytes, mostly in HL patients compared with B-NHL and control populations [9] .
We find that high JCV genome copy numbers are associated with the induction of chromosomal instability, as reflected by a significant increase in unstable chromosomal aberrations such as dicentric chromosomes and chromosome fragments in diploid metaphases, and this instability increases with progressive loss of viral genomes and proteins. The absence of JCV genome in hyperploid rogue lymphocytes observed in vitro testifies the progressive loss of JCV genome in PBL during the follow-up of patients [20] . A hit-and-run mechanism may be responsible for the lack of JCV genome copy number in Comparison between the proportion of patients with virus (>2 spots) in this group of patients and the proportion observed in HL patients. B-NHL, B-cell non-Hodgkin's lymphoma; EBV, Epstein-Barr virus; JCV, JC polyomavirus; NS, not significant.
Annals of Oncology original article
aneuploid rogue lymphocytes and the sequences in circulating lymphocytes 1 year after treatment. Such a mechanism is hypothesized in several cancers [21] . As previously indicated, chromosomal instability during the process of tumorigenesis may be responsible for deletion of viral genome leading to the inability to detect viral genome [22] . This has been indicated in colonic cancer [20] and a similar process has been evoked in EBV-negative HL [23] .
The role of JCV in lymphoma, on the basis of serological studies, is still under debate [24] . Serological data showed a high prevalence of JCV antibody in the present HL series, as compared with B-NHL patients and a normal healthy population (data not shown).
The mechanism of the interaction between EBV and JCV and its role in the induction of chromosomal instability is unknown. Several hypotheses, including genetic susceptibility, are currently under investigation [23, 25] .
Close correlations with an adverse clinical course (lower FFP) of HL were shown in case of EBV and/or JCV activation and in case of detection of rogue lymphocytes after treatment. Several reports correlated EBV and Hodgkin's outcome as recently reviewed [2] . Similar observations have been reported for EBV in Burkitt's lymphoma [26] particularly in HL and posttransplant lymphoproliferative disease [27, 28] .
These observations cast a new light on the role of EBV and JCV in the pathogenesis of HL. Monitoring the status of these viruses may contribute to anticipate the clinical course of the disease and lead to new antiviral and molecular strategies with cellular proteins. The genesis of rogue cells is intriguing. Freedom from progression 
